U.S. markets open in 3 hours 31 minutes

Century Therapeutics, Inc. (IPSC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
22.43+1.53 (+7.32%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close20.90
Open20.90
Bid0.00 x 1300
Ask0.00 x 1000
Day's Range20.86 - 22.55
52 Week Range18.92 - 32.90
Volume60,374
Avg. Volume240,707
Market Cap1.22B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-8.14
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Century Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 06/24/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    3 months agoArgus Research
View more
  • GlobeNewswire

    Century Therapeutics Announces Its Addition to the Russell 2000® Index

    PHILADELPHIA, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that it will be added to the small-cap Russell 2000® Index as a part of the 3Q21 Russell Indexes IPO additions, effective at US market open on September 20, 2021, according to the preliminary list of IPO additions to the Russell indexes. “Century’s inclusion in the Russe

  • GlobeNewswire

    Century Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates

    Continued Company investment across our iPSC platforms, programs, and manufacturingLead program, CNTY-101, remains on track for IND filing in mid-2022Recent IPO with net proceeds of approximately $221MJune 30, 2021 cash, cash equivalents, and marketable securities of $440M PHILADELPHIA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics, (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today reporte

  • GlobeNewswire

    Century Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    PHILADELPHIA, June 22, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the closing of its initial public offering of 12,132,500 shares of its common stock at a public offering price of $20.00 per share, which includes the full exercise by the underwriters of their option to purchase 1,582,500 additional shares of common stock. The aggregate